HENAN SUNLAKE ENTERPRISE CORPORATION
Free supplier Enterprise Certification
- Free
supplier - 9th
years
Free supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: +86-371- 86259723
Tel: 17734809689
Tel: 17734809689
Tel: 86-371-86259723
Tel: 17734809689
Tel: 17734809689
Mobile: 17734809689
Tel: +86-371- 86259723
Fax: +86-371- 86259723
Province/state: HENAN
City: ZHENGZHOU
Street: Mingmen International Center, NO.222 Dongming Road,Zhengzhou,Henan,China
MaxCard:
Contact Suppliers
CAS NO.21829-25-4
1(10-100)Kilogram1(100-500)Kilogram2(500-1000)Kilogram
1. Certificate Of Analysis (COA)
2. Material Safety Data Sheet (MSDS)
3. Route of synthesis (ROS)
4. Method of Aanlysis (MOA)
5. Nuclear Magnetic Resonance (NMR)
6. Packing pictures and loading video before loading
7. Free Sample
9. Factory audit
10. Strong after-sale service
| Product Name: | Nifedipine |
| Synonyms: | 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylicaciddime;3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester;4-(2’-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsaeuredimethy;5-pyridinedicarboxylicacid,1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-dim;Adalat CC;bay1040;corinfar;Dimethyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate |
| CAS: | 21829-25-4 |
| MF: | C17H18N2O6 |
| MW: | 346.34 |
| EINECS: | 244-598-3 |
| Product Categories: | Pharmaceutical;Active Pharmaceutical Ingredients;Dihydropyridine Class Chemicals;Functional Materials;Photopolymerization Initiators;Intermediates & Fine Chemicals;Pharmaceuticals;Calcium channel;Ion Channels;Dihydropyridine;Pharmaceutical intermediate;Isotopically Labeled Pharmaceutical Reference Standard;CAPOTEN;Cardiovascular APIs;Cardiovascular Drugs |
| Mol File: | 21829-25-4.mol |
|
|
|
| Nifedipine Chemical Properties |
| mp | 171-175 °C |
| storage temp. | 2-8°C |
| solubility | DMSO: soluble |
| form | powder |
| color | yellow |
| Water Solubility | <0.1 g/100 mL at 19.5 ºC |
| Merck | 6528 |
| CAS DataBase Reference | 21829-25-4(CAS DataBase Reference) |
| NIST Chemistry Reference | Nifedipine(21829-25-4) |
| EPA Substance Registry System | 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-( 2-nitrophenyl)-, dimethyl ester(21829-25-4) |
| Safety Information |
| Hazard Codes | Xn,Xi |
| Risk Statements | 22-36/37/38 |
| Safety Statements | 26-36 |
| WGK Germany | 1 |
| RTECS | US7975000 |
| HazardClass | IRRITANT |
| MSDS Information |
| Provider | Language |
|---|---|
| Nifedipine | English |
| SigmaAldrich | English |
| ACROS | English |
| Nifedipine Usage And Synthesis |
| Pharmacological effects |
Nifedipine is a kind of dihydropyridine calcium antagonists, it can inhibit the Ca2 + uptake of cardiac and vascular smooth muscles, and it can expand the coronary artery , increase coronary blood flow,and improve myocardial ischemic tolerance, at the same time, it can expand peripheral arteries and reduce peripheral vascular resistance,and relieve coronary artery spasm, and increase coronary blood flow, improve myocardial ischemia,in order to decrease the blood pressure. Small doses do not affect blood pressure, when expanding coronary artery ,it is a better anti-angina drug .It is used for the prevention and treatment of angina pectoris,with no adverse effects on respiratory function, its efficacy is best particularly for angina pectoris coronary spasm and obstructive airway disease with angina , its efficacy is superior to β-blockers.It is also applied to all types of high blood pressure, including severe and resistant hypertension. Treatment of refractory congestive heart failure may be taking this long. It is also used for the treatment of primary pulmonary hypertension, diffuse esophageal spasm and bronchial asthma, duodenal ulcers, urinary tract obstruction, exercise-induced asthma, achalasia. Nifedipine has a certain selectivity on vascular smooth muscles , the direct negative inotropic effect and denaturation effect on the heart are weak, systemic administration of it does not cause the heart rate slowing down ,on the contrary, the heart rate performances reflected increase. The above information is edited by the chemicalbook of Tian Ye. |
| Chemical properties | Yellow crystals. Melting point 172-174 ℃. Soluble in acetone, chloroform, ethyl acetate, dissolved in hot methanol, insoluble in water. It easily deteriorates in case of light. |
| Application | Long-term coronary vasodilators. This product can increase coronary blood flow, reducing myocardial oxygen consumption.it is used for acute and chronic coronary insufficiency,especially the angina and myocardial infarction. |
| Production methods | O-nitrobenzaldehyde, methyl acetoacetate, methanol, ammonia are refluxed together , then froze , crystallize,after filtration, nifedipine crude is obtained . The crude product is recrystallized through methanol .then the product is derived , yield rate is 50%. |
| Category | Toxic substances |
| Toxicity grading | Highly toxic |
| Acute toxicity | Oral - rat LD50: 1022 mg / kg; Oral - Mouse LD50: 310 mg / kg. |
| Flammability and hazard characteristics | Combustion produces toxic fumes of nitrogen oxides; medicinal side effects: low blood pressure, cardiac disease, local blood flow disease, high blood sugar, psychosis. |
| Storage Characteristics | Ventilated , low-temperature, drying; and it is kept separately from food raw materials warehouse. |
| Extinguishing agent | Dry powder, foam, sand, carbon dioxide, water spray. |
| Chemical Properties | Yellow Crystalline Solid |
| Usage | Used as an antihypertensive and antianginal. A dihydorpyridine calcium channel blocker |
| Usage | For the management of vasospastic angina, chronic stable angina, hypertension, and Raynaud's phenomenon. May be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension (long-acting agents). |
| General Description | Odorless yellow crystals or powder. Tasteless. |
| Air & Water Reactions | Aqueous solutions are very sensitive to light. . Insoluble in water. |
| Reactivity Profile | Nifedipine is sensitive to light. |
| Fire Hazard | Flash point data for Nifedipine are not available; however, Nifedipine is probably combustible. |
| Biological Activity | L-type calcium channel blocker. |
| Product Name: | Nifedipine |
| Synonyms: | 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylicaciddime;3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester;4-(2’-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsaeuredimethy;5-pyridinedicarboxylicacid,1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-dim;Adalat CC;bay1040;corinfar;Dimethyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate |
| CAS: | 21829-25-4 |
| MF: | C17H18N2O6 |
| MW: | 346.34 |
| EINECS: | 244-598-3 |
| Product Categories: | Pharmaceutical;Active Pharmaceutical Ingredients;Dihydropyridine Class Chemicals;Functional Materials;Photopolymerization Initiators;Intermediates & Fine Chemicals;Pharmaceuticals;Calcium channel;Ion Channels;Dihydropyridine;Pharmaceutical intermediate;Isotopically Labeled Pharmaceutical Reference Standard;CAPOTEN;Cardiovascular APIs;Cardiovascular Drugs |
| Mol File: | 21829-25-4.mol |
|
|
|
| Nifedipine Chemical Properties |
| mp | 171-175 °C |
| storage temp. | 2-8°C |
| solubility | DMSO: soluble |
| form | powder |
| color | yellow |
| Water Solubility | <0.1 g/100 mL at 19.5 ºC |
| Merck | 6528 |
| CAS DataBase Reference | 21829-25-4(CAS DataBase Reference) |
| NIST Chemistry Reference | Nifedipine(21829-25-4) |
| EPA Substance Registry System | 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-( 2-nitrophenyl)-, dimethyl ester(21829-25-4) |
| Safety Information |
| Hazard Codes | Xn,Xi |
| Risk Statements | 22-36/37/38 |
| Safety Statements | 26-36 |
| WGK Germany | 1 |
| RTECS | US7975000 |
| HazardClass | IRRITANT |
| MSDS Information |
| Provider | Language |
|---|---|
| Nifedipine | English |
| SigmaAldrich | English |
| ACROS | English |
| Nifedipine Usage And Synthesis |
| Pharmacological effects |
Nifedipine is a kind of dihydropyridine calcium antagonists, it can inhibit the Ca2 + uptake of cardiac and vascular smooth muscles, and it can expand the coronary artery , increase coronary blood flow,and improve myocardial ischemic tolerance, at the same time, it can expand peripheral arteries and reduce peripheral vascular resistance,and relieve coronary artery spasm, and increase coronary blood flow, improve myocardial ischemia,in order to decrease the blood pressure. Small doses do not affect blood pressure, when expanding coronary artery ,it is a better anti-angina drug .It is used for the prevention and treatment of angina pectoris,with no adverse effects on respiratory function, its efficacy is best particularly for angina pectoris coronary spasm and obstructive airway disease with angina , its efficacy is superior to β-blockers.It is also applied to all types of high blood pressure, including severe and resistant hypertension. Treatment of refractory congestive heart failure may be taking this long. It is also used for the treatment of primary pulmonary hypertension, diffuse esophageal spasm and bronchial asthma, duodenal ulcers, urinary tract obstruction, exercise-induced asthma, achalasia. Nifedipine has a certain selectivity on vascular smooth muscles , the direct negative inotropic effect and denaturation effect on the heart are weak, systemic administration of it does not cause the heart rate slowing down ,on the contrary, the heart rate performances reflected increase. The above information is edited by the chemicalbook of Tian Ye. |
| Chemical properties | Yellow crystals. Melting point 172-174 ℃. Soluble in acetone, chloroform, ethyl acetate, dissolved in hot methanol, insoluble in water. It easily deteriorates in case of light. |
| Application | Long-term coronary vasodilators. This product can increase coronary blood flow, reducing myocardial oxygen consumption.it is used for acute and chronic coronary insufficiency,especially the angina and myocardial infarction. |
| Production methods | O-nitrobenzaldehyde, methyl acetoacetate, methanol, ammonia are refluxed together , then froze , crystallize,after filtration, nifedipine crude is obtained . The crude product is recrystallized through methanol .then the product is derived , yield rate is 50%. |
| Category | Toxic substances |
| Toxicity grading | Highly toxic |
| Acute toxicity | Oral - rat LD50: 1022 mg / kg; Oral - Mouse LD50: 310 mg / kg. |
| Flammability and hazard characteristics | Combustion produces toxic fumes of nitrogen oxides; medicinal side effects: low blood pressure, cardiac disease, local blood flow disease, high blood sugar, psychosis. |
| Storage Characteristics | Ventilated , low-temperature, drying; and it is kept separately from food raw materials warehouse. |
| Extinguishing agent | Dry powder, foam, sand, carbon dioxide, water spray. |
| Chemical Properties | Yellow Crystalline Solid |
| Usage | Used as an antihypertensive and antianginal. A dihydorpyridine calcium channel blocker |
| Usage | For the management of vasospastic angina, chronic stable angina, hypertension, and Raynaud's phenomenon. May be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension (long-acting agents). |
| General Description | Odorless yellow crystals or powder. Tasteless. |
| Air & Water Reactions | Aqueous solutions are very sensitive to light. . Insoluble in water. |
| Reactivity Profile | Nifedipine is sensitive to light. |
| Fire Hazard | Flash point data for Nifedipine are not available; however, Nifedipine is probably combustible. |
| Biological Activity | L-type calcium channel blocker. |